Open access
12 | LEBRIKIZUMAB FOR PAEDIATRIC PATIENTS AGED ≥6 MONTHS WITH MODERATE-TO-SEVERE AD: PHASE 3 ADORABLE-1 WEEK-16 RESULTS
Abstract
Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin condition impacting 15—20% of children globally, with limited treatment options. Lebrikizumab (LEB) inhibits interleukin (IL)-13, a key driver of AD, and is approved for patients (pts) ≥12 years (y), ≥40kg with moderate-to-severe (mod-sev) AD inadequately treated with topicals. The ADorable 1 double-blind phase 3 study (NCT05559359) evaluated 16 week (W) efficacy and safety of LEB and topical corticosteroids (TCS) vs placebo (PBO) and TCS in pts aged 6 months (m) to